Question

Mirvetuximab soravtansine.

Hint:

Mirvetuximab soravtansine is an exciting new option in targeted cancer therapy, offering potential for specific tumor destruction with minimal side effects.

Answer 1

Mirvetuximab soravtansine is an antibody-drug conjugate that targets the folate receptor alpha (FRα), which is overexpressed in certain types of cancer, particularly ovarian cancer. It consists of a monoclonal antibody linked to a cytotoxic agent, which is released into cancer cells upon binding to FRα.
Step 1: Mechanism of Action:
The antibody portion of Mirvetuximab soravtansine binds to FRα, and the cytotoxic drug is internalized into the cell. The drug then disrupts cellular processes, leading to cancer cell death.
Step 2: Clinical Uses:
Mirvetuximab soravtansine is being investigated in clinical trials for the treatment of ovarian cancer and other cancers expressing FRα.
Step 3: Dosage and Administration:
The recommended dosing schedule is determined by the clinical trial protocols, as Mirvetuximab soravtansine is still under investigation for certain indications.